Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
EFNB3 Biologics Sequence Review Report 2026: Ephrin-B3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNB3 Biologics Sequence Review Report 2026: Ephrin-B3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EFNB2 Biologics Sequence Review Report 2026: Ephrin-B2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNB2 Biologics Sequence Review Report 2026: Ephrin-B2 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNB2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EFNB1 Biologics Sequence Review Report 2026: Ephrin-B1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNB1 Biologics Sequence Review Report 2026: Ephrin-B1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EFNA5 Biologics Sequence Review Report 2026: Ephrin-A5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNA5 Biologics Sequence Review Report 2026: Ephrin-A5 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNA5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EFNA4 Biologics Sequence Review Report 2026: Ephrin-A4 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNA4 Biologics Sequence Review Report 2026: Ephrin-A4 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNA4 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EFNA3 Biologics Sequence Review Report 2026: Ephrin-A3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNA3 Biologics Sequence Review Report 2026: Ephrin-A3 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNA3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EFNA1 Biologics Sequence Review Report 2026: Ephrin-A1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNA1 Biologics Sequence Review Report 2026: Ephrin-A1 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of EFNA1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL9 Biologics Sequence Review Report 2026: C-X-C motif chemokine 9 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL9 Biologics Sequence Review Report 2026: C-X-C motif chemokine 9 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL9 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL6 Biologics Sequence Review Report 2026: C-X-C motif chemokine 6 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL6 Biologics Sequence Review Report 2026: C-X-C motif chemokine 6 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL5 Biologics Sequence Review Report 2026: C-X-C motif chemokine 5 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL5 Biologics Sequence Review Report 2026: C-X-C motif chemokine 5 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL17 Biologics Sequence Review Report 2026: C-X-C motif chemokine 17 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL17 Biologics Sequence Review Report 2026: C-X-C motif chemokine 17 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL17 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCL16 Biologics Sequence Review Report 2026: C-X-C motif chemokine 16 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCL16 Biologics Sequence Review Report 2026: C-X-C motif chemokine 16 Similarity and Patent-Risk Signals
6 August 2026
A Biology Modality MCP review of CXCL16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →